inspiring canadians to live better.

healthing leaf

inspiring canadians to live better.

healthing leaf
get healthing in your inbox with the morning checkup and weekender newsletter!

fda approves janssen's cancer therapy for people with myeloma

the treatment offers hope for patients who have already undergone four or more other lines of therapy.

by chris arnold
published mar 03, 2022
read time 3 minute read
join the conversation
read time 3 minute read
join the conversation
fda approves janssen's cancer therapy for people with myeloma
carvykti requires a significant amount of preparation and training for doctors and nurses to properly treat patients. getty
a new cell-based treatment for blood cancer developed by johnson & johnson and its china-based partner legend biotech corp is now fda-approved for use in the united states. carvykti, a chimeric antigen receptor t-cell therapy, is designed for use in people with multiple myeloma, a form of blood cancer. the treatment will be used on patients who have already undergone four or more other lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and a monoclonal antibody.
“we are committed to harnessing our science, deep disease understanding and capabilities to bring forward cell therapies like carvykti as we continue to focus on our ultimate goal of delivering a cure for multiple myeloma,” peter lebowitz, global therapeutic area head of oncology at janssen research & development said. “we extend our sincere gratitude to the patients, their families and the teams of researchers and study centres who have participated in the clinical study of carvykti and enabled today’s approval.”
one of j&j’s studies, dubbed cartitde-1, which factored significantly into the approval process, found 98 per cent of patients responded to the treatment. additionally, 78 per cent experienced such a positive response that doctors were not able to see any signs of multiple myeloma at a follow up appointment, which was roughly two years after the treatment.

related stories

almost one-third of canadian clinical care ‘deemed inappropriate’
not enough use of blood tests and radiology leads to negative patient experiences, poor health outcomes and an inefficient use of resources, the researchers found.
researchers found that inappropriate treatment led to poor health outcomes and an inefficient use of resources. getty

opinion: rushing quebec’s bill 2 risks leaving many voices unheard
the controversial bill introduces new (and highly criticized) rules regarding trans and non-binary individuals’ rights to modify their sex designations and gender markers on identity documents.
advocates say the government failed to adequately consult with the lgbtq+ community prior to introducing the bill. getty
story continues below
carvykti requires a significant amount of preparation and training for doctors and nurses to properly treat patients, so much so that certification courses will be offered by janssen and legend biotech, the companies that helped develop the treatment.
a limited network of certified treatment centres will start providing care in the united states later this year, with more planned to be established in the near future.

a vision for ‘eliminating cancer’

“this approval of janssen’s first cell therapy is a testament to our continuing commitment in oncology to deliver new therapeutic options and drive toward our vision of the elimination of cancer,” mathai mammen, executive vice president of pharmaceuticals at janssen r&d and johnson & johnson said. “today’s approval underscores our determination to develop therapies that can help patients living with what remains an intractable blood cancer today and at the same time offer hope for the future.”
the response to the study, and the 18-month follow up to monitor patients longer term, showed the treatment has durability over time, sundar jagnnath, director of the centre of excellence for multiple myeloma and principal study investigator said, adding that the approval of the treatment provides an opportunity for therapy that can let patients live myeloma-free for a period of time.
powered by
the leukemia & lymphoma society of canada (llsc)
story continues below
researchers are still looking into the long-term efficacy and safety of the treatment to determine how effective it will be in the future, though a 22-month follow up found that 83 per cent of patients were still responding positively.
multiple myeloma is an incurable blood cancer caused by a buildup of abnormal plasma cells, or white blood cells that make antibodies, in bone marrow, according to the canadian cancer society. the disease makes it difficult for the bone marrow to develop, which can cause anemia and fatigue due to a reduced amount of red blood cells. multiple myeloma can also cause bone tumours. despite some treatments being available, the five-year survival rate for multiple myeloma is 54 per cent.
most myeloma patients (male and female) are diagnosed between 70 to 80 years of age, reports myeloma canada — people under the age of 45 make up just four per cent of those diagnoses.
it is estimated that in 2021, 3,800 canadians were diagnosed with multiple myeloma — 2,300 men and 1,500 women, the canadian cancer society reports. additionally, 1,600 of the 3,800 diagnosed are estimated to have died. 
chris arnold is a toronto-based writer.
story continues below
thank you for your support. if you liked this story, please send it to a friend. every share counts.

comments

postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. comments may take up to an hour for moderation before appearing on the site. we ask you to keep your comments relevant and respectful. we have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. visit our community guidelines for more information and details on how to adjust your email settings.

you may also like
doctor during consultation held in his hand and shows patient laboratory tube with blood. counseling of transfusion, blood and hematologic diseases and pathology like anemias, cell cancer, hemophilia
blood cancer in canada: stats, impact and resources 
rinat avitzur posing for a photo with her family of three daughters and husband.
what it feels like: 'i will find ways to make cancer easier for people like myself’
caregiver and his wife with blood cancer
how i care for multiple myeloma: 'i want to believe there will be a cure in our lifetime'
human hands hold a heart in line art
machado: joining a clinical trial was the best decision i ever made
092621-walk_264848367-w
annual multiple myeloma march goes virtual
you may also like
doctor during consultation held in his hand and shows patient laboratory tube with blood. counseling of transfusion, blood and hematologic diseases and pathology like anemias, cell cancer, hemophilia
blood cancer in canada: stats, impact and resources 
rinat avitzur posing for a photo with her family of three daughters and husband.
what it feels like: 'i will find ways to make cancer easier for people like myself’
caregiver and his wife with blood cancer
how i care for multiple myeloma: 'i want to believe there will be a cure in our lifetime'
human hands hold a heart in line art
machado: joining a clinical trial was the best decision i ever made
you may also like
doctor during consultation held in his hand and shows patient laboratory tube with blood. counseling of transfusion, blood and hematologic diseases and pathology like anemias, cell cancer, hemophilia
blood cancer in canada: stats, impact and resources 
rinat avitzur posing for a photo with her family of three daughters and husband.
what it feels like: 'i will find ways to make cancer easier for people like myself’